Kento Takenaka

Tokyo Medical and Dental University
Country flagJapan
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (5)

Background and aims Clinicians need data on the responsiveness of ileal strictures of Crohn’s disease (CD) to biologic therapy, yet most trials prioritize mucosal healing. We quantified short‑term changes in ileal strictures under biologic treatment and evaluated their prognostic relevance. Patients and methods In a post hoc analysis of a prospective cohort, consecutive patients with ileal or ileocolonic CD initiating or switching a biologic (anti‑tumor necrosis factor [TNF], ustekinumab [UST], or vedolizumab [VDZ]) underwent segment‑specific endoscopic assessment at baseline and 6 months. The primary outcome was resolution or progression of strictures at 6 months. Secondary outcomes included time‑to‑event analyses for hospitalization and surgery. Results Among the 170 patients, the 6‑month stricture resolution and progression rates were 30.9% and 15.7%, respectively. There were no significant differences in stricture dynamics between anti‑TNF agents, UST, and VDZ (P = .443 for resolution and P = .167 for progression). Baseline strictures did not predict outcomes; however, strictures present at 6 months were associated with higher risks of hospitalization (P = .006) and surgery (P = .024), particularly when located in the non-terminal ileum. Clinical, biochemical, and endoscopic activity improved overall during follow‑up. Conclusions The 6‑month stricture status, especially non-terminal ileal disease, carried prognostic significance. Because stricture dynamics did not differ across biologic classes, the presence of strictures alone should not constrain agent selection.

Year:

2026

Introduction: Immune-related adverse events (irAEs), which occur due to loss of immune tolerance, represent a significant challenge when using immune checkpoint inhibitors (ICIs). As the indications for ICIs continue to expand, the incidence of irAEs has been increasing. Immune-mediated diarrhea and colitis (IMDC) is one of the most frequent irAEs. Although important for the management of IMDCs, colonoscopy is highly invasive for patients with cancer, and development of noninvasive alternatives is needed. Methods: We prospectively enrolled patients diagnosed with IMDC between May 2019 and May 2025, and a total of 34 patients were included in the final analysis. Blood and stool samples were collected, and biomarker levels were measured. Endoscopic activity was defined as a Mayo Endoscopic Subscore of ≥2, as evaluated during colonoscopy. The relationship of each biomarker with endoscopic activity was examined using Spearman’s rank correlation and receiver operating characteristic curve analysis. Results: Fecal calprotectin (FC), fecal lactoferrin (FL), and fecal immunochemical test (FIT) were significantly correlated with the Mayo Endoscopic Subscore, with correlation coefficients of 0.50, 0.51, and 0.74, respectively. These biomarkers effectively detected endoscopic activity, with high area under the curve values of 0.79, 0.81, and 0.94, respectively. Furthermore, certain combinations of fecal biomarkers enhanced accuracy, as demonstrated by FC (+) or FIT (+), which achieved a sensitivity of 95.5% and a specificity of 75.0%. Conclusion: Fecal biomarkers were correlated with endoscopic activity and effectively identified patients with endoscopically active IMDC. Our findings suggest that these biomarkers may be valuable tools for the diagnosis and assessment of treatment response in IMDC.

Year:

2025

Introduction: No real-world studies have compared efficacy of ustekinumab (UST) and risankizumab (RZB) for the treatment of Crohn’s disease (CD). Methods: We retrospectively collected the data of patients with CD treated with UST or RZB between May 2017 and March 2024 at the Institute of Science Tokyo and analyzed clinical remission rate at weeks 8 and 28 using Harvey-Bradshaw Index (HBI), with remission defined as a HBI ≤4. Result: A total of 111 patients who were treated with UST and 29 patients treated with RZB were included in the analysis. RZB had higher efficacy both at weeks 8 (82.8% vs. 62.2%, p = 0.0465) and 28 (79.3% vs. 56.8%, p = 0.0321) than UST in the full study cohort, and at weeks 8 (55.6% vs. 18.4%, p = 0.0352) and 28 (66.7% vs. 18.4%, p = 0.0083) in the patients with clinically active disease and anti-TNFα exposed patients. During the observation period, 1 patient with RZB (3.45%) experienced an adverse event that required hospitalization, and 1 patient in the UST group (0.900%) experienced an adverse event that led to treatment discontinuation. Conclusion: RZB may offer greater short-term efficacy than UST, with an acceptable safety profile in real-world settings.

Year:

2025

Inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, presents substantial diagnostic and management challenges because of its variable clinical course and the limitations of conventional endoscopy. Although endoscopic procedures are crucial for diagnosis and surveillance, their inherent subjectivity and inter‐observer variability complicate disease assessment. Recent advances in artificial intelligence (AI) offer promising solutions to these challenges by enabling automated, precise, and objective image analysis. AI technologies have demonstrated success in diagnosing IBD, distinguishing it from other gastrointestinal disorders, and facilitating early identification of neoplasia in IBD patients, improving clinical decision‐making and potentially reducing the need for invasive procedures. Furthermore, AI applications for evaluating endoscopic images have enhanced the accuracy of disease severity assessments such as the Mayo Endoscopic Score and Ulcerative Colitis Endoscopic Index of Severity by overcoming issues related to observer variability. Integration of AI with advanced endoscopic technologies, including image‐enhanced and magnified endoscopy, further improves lesion characterization and offers insights into mucosal healing, which is crucial for optimizing treatment. While AI's potential in IBD management is substantial, challenges remain in its clinical implementation, necessitating further validation through real‐world data and regulatory approval. This review explores the evolving role of AI in transforming IBD diagnosis, surveillance, and assessment, with a focus on enhancing patient care through improved precision and efficiency.

Year:

2025

In recent years, we have seen a considerable increase in the number of patients with inflammatory bowel diseases of unknown etiology, including both Crohn's disease and ulcerative colitis. Inflammatory bowel diseases can cause intestinal lesions throughout the gastrointestinal tract, necessitating gastrointestinal endoscopy for examining all relevant aspects, especially lesion characteristics, for differential diagnosis and histological diagnosis, to select the appropriate treatment options, determine treatment effectiveness, etc. Specific guidelines are necessary to ensure that endoscopy can be performed in a safe and more tailored and efficient manner, especially since gastrointestinal endoscopy, including enteroscopy, is a common procedure worldwide, including in Japan. Within this context, the Japan Gastroenterological Endoscopy Society has formulated the “Guidelines for the Endoscopic Diagnosis and Treatment of Inflammatory Bowel Diseases” to provide detailed guidelines regarding esophagogastroduodenoscopy, enteroscopy, and colonoscopy procedures for definitive diagnosis, as well as determination of treatment effectiveness in clinical cases of inflammatory bowel diseases.

Year:

2025

Collaborators (8)

Toshimitsu Fujii

Tokyo Institute of Technology

JAPAN
View details

Tadakazu Hisamatsu

-

JAPAN
View details

Masashi Misawa

-

JAPAN
View details

Hiroshi Nakase

Dean

-

JAPAN
View details

Motohiro Esaki

Professor

Saga University

JAPAN
View details

Marietta Iacucci

University of Birmingham

UNITED KINGDOM
View details

Ryuichi Okamoto

Tokyo Medical and Dental University

JAPAN
View details

Mitsuhiro Fujishiro

Professor

Nagoya University

JAPAN
View details